Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11099111 | 0.84 | AR (0.52) | CFTRMAPTPLA2G2APTGDR2ALDH1A1 | |
| SCHEMBL11095519 | 0.84 | CFTR (0.48) | DCTPP1CFTRMAPTPLA2G2AAGTR1 | |
| SCHEMBL8954292 | 0.82 | ALDH1A1 (0.49) | AGTR1AGTR2PTGDR2ALDH1A1LMNA | |
| SCHEMBL11166536 | 0.82 | PTGDR2 (0.49) | CFTRPLA2G2AAGTR1AGTR2PTGDR2 | |
| SCHEMBL11093449 | 0.78 | ALDH1A1 (0.48) | PLA2G2AAGTR1AGTR2ALDH1A1LMNA | |
| SCHEMBL11092577 | 0.77 | CASR (0.47) | PLA2G2AAGTR1AGTR2ALDH1A1LMNA | |
| SCHEMBL6227119 | 0.77 | ALDH1A1 (0.43) | PLA2G2AAGTR1AGTR2ALDH1A1LMNA | |
| SCHEMBL11090546 | 0.77 | ALDH1A1 (0.54) | AGTR1AGTR2PTGDR2ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL5331525 | 0.76 | AGTR1 (0.42) | PLA2G2AAGTR1AGTR2ALDH1A1LMNA | |
| SCHEMBL11092145 | 0.76 | LMNA (0.43) | CFTRPLA2G2AALDH1A1LMNACCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4355040-A | Hypotensive imidazole-5-acetic acid derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-10-19 | — | — | US | claimed |
| US-20030187044-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-10-02 | — | — | US | disclosed |
| US-20030166700-A1 | Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression | SMITHKLINE BEECHAM P.L.C. | 2003-09-04 | — | — | US | disclosed |
| US-20030096851-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-05-22 | — | — | US | disclosed |
| EP-0724387-B1 | ANGIOTENSION II RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030069293-A1 | Medicament | SMITHKLINE BEECHAM PLC | 2003-04-10 | — | — | US | disclosed |
| US-20030050285-A1 | Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke | SMITHKLINE BEECHAM P.L.C. | 2003-03-13 | — | — | US | disclosed |
| US-20030004201-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-01-02 | — | — | US | disclosed |
| US-20020160985-A1 | Medicament | SMITHKLINE BEECHAM PLC | 2002-10-31 | — | — | US | disclosed |
| US-20020132840-A1 | Treating angina in a mammal by administering an angiotensin II receptor antagonist. | SMITHKLINE BEECHAM P.1.C. | 2002-09-19 | — | — | US | disclosed |
| WO-1992010185-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE PREVENTION OF RESTINOSIS | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010186-A1 | USE OF ANGIOTENSN II RECEPTOR ANTAGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR IMPROVING COGNITIVE FUNCTION | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010183-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC RETINOPATHY | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010182-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC NEPHROPATHY | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010179-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF MACULAR DEGENERATION | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010187-A1 | USE OF ANGIOTENSIN II ANTAGONISTS IN THE TREATMENT OF ANGINA PECTORIS | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| US-5036048-A | Angiotensin II receptor blockers as antiglaucoma agents | SCHERING CORPORATION (US) | 1991-07-30 | — | — | US | disclosed |
| EP-0028834-B1 | IMIDAZOLE-5-ACETIC ACID DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1984-01-18 | — | — | EP | disclosed |
| US-4355040-A | Hypotensive imidazole-5-acetic acid derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-10-19 | — | — | US | disclosed |
| EP-0028834-A1 | Imidazole-5-acetic acid derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1981-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160985-A1 | Medicament | AGTR2, AGTR1, ACE | DCTPP1 1571/4885CFTR 1586/4885MAPT 4286/4885 |
| US-20020132840-A1 | Treating angina in a mammal by administering an angiotensin II receptor antagonist. | AGTR2, AGTR1, AGT | DCTPP1 1018/4885CFTR 3485/4885MAPT 2998/4885 |
| US-20030187044-A1 | Medicament | AGTR2, AGTR1, ACE | DCTPP1 2045/4885CFTR 3082/4885MAPT 425/4885 |
| US-20030004201-A1 | Medicament | AGTR2, AGTR1, ACE | DCTPP1 1818/4885CFTR 1621/4885MAPT 3123/4885 |
| US-20030166700-A1 | Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression | AGTR1, AGTR2, AGT | DCTPP1 3449/4885CFTR 4169/4885MAPT 1552/4885 |
| US-20030096851-A1 | Medicament | AGTR2, AGTR1, ACE | DCTPP1 2045/4885CFTR 3082/4885MAPT 425/4885 |
| US-20030050285-A1 | Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke | AGTR2, AGTR1, ACE | DCTPP1 4006/4885CFTR 3269/4885MAPT 1662/4885 |
| US-20030069293-A1 | Medicament | AGTR2, AGTR1, ACE | DCTPP1 1571/4885CFTR 1586/4885MAPT 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.